The Motley Fool
Why Summit Therapeutics Skyrocketed 123% This Week | The Motley Fool
A biotech stock surging that much usually means a new blockbuster drug candidate either posted good trial data or was approved for use. Last weekend, Summit announced the results of its Harmoni ...
3 hours ago